Sodium Valproate in Therapy of Interactable Headaches with Eeg Changes.

Viswanathan, K N; Sundraram, N.; Rajendiran, C; Manohar, Deepa; Balaraman, Vasanthi

doi:10.1177/0333102491011s11151

Cited by 6 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we did not record neither the patients' headache frequency nor severity over 12 weeks but it may be assumed there is an additional effect over 12 weeks, and future controlled studies should be extended to 16 weeks or longer. The effect on headache severity and frequency has been reported to be irrelevant of its anticonvulsant activity, as there was no correlation between the degree of improvement in headache and the occurrence of EEG abnormality or seizure (13,22).…”

Section: Discussionmentioning

confidence: 99%

Valproic acid in prophylaxis of refractory migraine

Erdemoğlu

Özbakır

2000

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Valproic acid in prophylaxis of refractory migraine

Erdemoğlu

Özbakır

2000

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

“…In 1991, Viswanathan et al 19 conducted an open study on 16 patients who had resistant migraine and paroxysmal EEG changes. The patients were treated with sodium valproate, 200 mg three times a day as an add-on medication.…”

mentioning

confidence: 99%

Divalproex Sodium in Headache: Literature Review and Clinical Guidelines

Silberstein¹

1996

Headache

View full text Add to dashboard Cite

Divalproex sodium is an anticonvulsant agent approved for use either alone or in combination with other antiepileptic drugs for simple and complex absences seizures and mania. Four double-blind placebo-controlled studies have confirmed that divalproex sodium/valproate is an effective migraine treatment. In all of the clinical studies, whether open, retrospective, or placebo-controlled and double-blind, valproate was an effective preventive treatment for migraine. There was a reduction in the number of migraine attacks, and migraine duration and intensity were also reduced in some instances. It is equally as effective in patients with severe frequent migraines as in those with less severe migraines. In clinical trials, the most frequent adverse events reported by patients treated with divalproex sodium were nausea, asthenia, dyspepsia, dizziness, somnolence, and diarrhea, with most adverse events being mild to moderate in severity.

show abstract

“…Divalproex sodium, a 1:1 mixture of valproic acid and valproate sodium, is an agonist of gamma amino butyric acid (GABA), which inhibits the activity of these cells and in theory may raise the headache threshold (3,4). Studies of divalproex for prophylaxis of trigeminal neuralgia (5), cluster headache (6), and migraine (7)(8)(9) have demonstrated substantial benefit. In the investigation reported here we sought to evaluate the safety, tolerability, and relative efficacy of divalproex when administered to three subpopulations of patients with intractable primary headache syndromes.…”

mentioning

confidence: 99%

A Differential Response to Treatment With Divalproex Sodium in Patients With Intractable Headache

et al. 1994

View full text Add to dashboard Cite

We consecutively recruited 75 patients with intractable headache syndromes, divided them into three groups (frequent migraine = FM, transformed migraine = TM, and tension type headache = TT) based on their headache symptoms and treated all 75 with divalproex sodium. Thirty-six patients (48%) reported a > or = 50% reduction in headache frequency. We noted significantly different treatment response rates in the three patient groups, with FM patients reporting the highest rate of improvement (11/18 = 61%), TM patients an intermediate rate (22/43 = 51%), and TT patients the lowest response rate (3/14 = 21%). These data suggest that prophylactic therapy with divalproex may be effective in selected patients with intractable headache syndromes and that identification of clinically distinct headache subtypes may assist in predicting response to treatment.

show abstract

Sodium Valproate in Therapy of Interactable Headaches with Eeg Changes.

Cited by 6 publications

References 5 publications

Valproic acid in prophylaxis of refractory migraine

Valproic acid in prophylaxis of refractory migraine

Divalproex Sodium in Headache: Literature Review and Clinical Guidelines

A Differential Response to Treatment With Divalproex Sodium in Patients With Intractable Headache

Contact Info

Product

Resources

About